Does NIVOLUMAB Cause Hypertransaminasaemia? 139 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 139 reports of Hypertransaminasaemia have been filed in association with NIVOLUMAB (OPDIVO). This represents 0.2% of all adverse event reports for NIVOLUMAB.
139
Reports of Hypertransaminasaemia with NIVOLUMAB
0.2%
of all NIVOLUMAB reports
15
Deaths
53
Hospitalizations
How Dangerous Is Hypertransaminasaemia From NIVOLUMAB?
Of the 139 reports, 15 (10.8%) resulted in death, 53 (38.1%) required hospitalization, and 9 (6.5%) were considered life-threatening.
Is Hypertransaminasaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NIVOLUMAB. However, 139 reports have been filed with the FAERS database.
What Other Side Effects Does NIVOLUMAB Cause?
Death (11,216)
Malignant neoplasm progression (9,363)
Off label use (5,208)
Diarrhoea (4,692)
Fatigue (3,709)
Pyrexia (3,454)
Intentional product use issue (3,297)
Rash (2,816)
Nausea (2,805)
Decreased appetite (2,619)
What Other Drugs Cause Hypertransaminasaemia?
METHOTREXATE (436)
ACETAMINOPHEN (326)
PACLITAXEL (318)
CARBOPLATIN (304)
PEMBROLIZUMAB (231)
ATORVASTATIN (207)
CYCLOPHOSPHAMIDE (202)
PREDNISONE (198)
GEMCITABINE (196)
DEXAMETHASONE (169)
Which NIVOLUMAB Alternatives Have Lower Hypertransaminasaemia Risk?
NIVOLUMAB vs NIVOLUMAB\RELATLIMAB-RMBW
NIVOLUMAB vs NIZATIDINE
NIVOLUMAB vs NOMEGESTROL
NIVOLUMAB vs NORDAZEPAM
NIVOLUMAB vs NOREPINEPHRINE